

# R&D Pipeline – Pharma & Vaccines

## Phase 1

## Phase 2

## Phase 3

## Registration

<p><b>SAR440340</b> <span>N</span></p> <p>Anti-IL33 mAb Asthma &amp; COPD</p>	<p><b>SAR438335</b> <span>N</span></p> <p>GLP-1R/GIPR dual agonist Type 2 Diabetes</p>	<p><b>dupilumab</b> <span>N</span></p> <p>Anti-IL4Ra mAb Eosinophilic Esophagitis</p>	<p><b>efpeglenatide</b> <span>N</span></p> <p>Long-acting GLP-1 receptor agonist Type 2 Diabetes</p>	<p><b>dupilumab</b> <span>N</span></p> <p>Anti-IL4Ra mAb Asthma, Nasal Polyposis</p>	<p><b>VaxiGrip® QIV IM</b></p> <p>Quadrivalent inactivated influenza vaccine (6-35 months)</p>
<p><b>SAR439794</b> <span>N</span></p> <p>TLR4 agonist Peanut Allergy</p>	<p><b>SAR440181<sup>(1)</sup></b> <span>N</span></p> <p>DCM1 Myosin activation Dilated Cardiomyopathy</p>	<p><b>SAR156597</b> <span>N</span></p> <p>IL4/IL13 Bi-specific mAb Systemic Scleroderma</p>	<p><b>SAR425899</b> <span>N</span></p> <p>GLP-1R/GCGR dual agonist Type 2 Diabetes</p>	<p><b>isatuximab</b> <span>N</span></p> <p>Anti-CD38 naked mAb Relapsed Refractory Multiple Myeloma</p>	<p><b>PR5i</b></p> <p>DTP-HepB-Polio-Hib Pediatric hexavalent vaccine, U.S</p>
<p><b>GZ402668</b> <span>N</span></p> <p>GLD52 (anti-CD52 mAb) Relapsing Multiple Sclerosis</p>	<p><b>SAR247799</b> <span>N</span></p> <p>S1P1 agonist Cardiovascular indication</p>	<p><b>GZ389988</b> <span>N</span></p> <p>TRKA antagonist Osteoarthritis</p>	<p><b>mavacamten<sup>(5)</sup></b> <span>N</span></p> <p>Myosin inhibitor Hypertrophic Cardiomyopathy</p>	<p><b>cemiplimab<sup>(4)</sup></b> <span>N</span></p> <p>PD-1 inhibitor 1<sup>st</sup> line NSCLC, BCC, 2<sup>nd</sup> line Cervical Cancer</p>	
<p><b>UshStat®</b> <span>N</span></p> <p>Myosin 7A gene therapy Usher Syndrome 1B</p>	<p><b>Herpes Simplex Virus Type 2</b></p> <p>HSV-2 vaccine</p>	<p><b>SAR100842</b> <span>N</span></p> <p>LPA1 receptor antagonist Systemic Sclerosis</p>	<p><b>SAR407899</b> <span>N</span></p> <p>rho kinase Microvascular Angina</p>	<p><b>patisiran</b> <span>N</span></p> <p>siRNA inhibitor targeting TTR Hereditary ATTR amyloidosis</p>	
<p><b>SAR228810</b> <span>N</span></p> <p>Anti-protofibrillar AB mAb Alzheimer's Disease</p>	<p><b>Respiratory syncytial virus</b></p> <p>Infants</p>	<p><b>SAR422459</b> <span>N</span> <span>R</span></p> <p>ABCA4 gene therapy Stargardt Disease</p>	<p><b>Combination ferroquine / OZ439</b> <span>N</span></p> <p>Antimalarial</p>	<p><b>GZ402666</b> <span>N</span></p> <p>neoGAA Pompe Disease</p>	
<p><b>SAR408701</b> <span>N</span></p> <p>Maytansin-loaded anti-CEACAM5 mAb Solid Tumors</p>		<p><span>R</span> <b>cemiplimab<sup>(4)</sup></b> <span>N</span></p> <p>PD-1 inhibitor Advanced CSCC (Skin cancer)</p>	<p><b>Rabies VRVg</b> <span>N</span></p> <p>Purified vero rabies vaccine</p>	<p><b>fitusiran<sup>(6)</sup></b> <span>N</span></p> <p>siRNA targeting Anti-Thrombin Hemophilia</p>	<p><span>N</span> New Molecular Entity</p>
<p><b>SAR428926</b> <span>N</span></p> <p>Maytansin-loaded anti-Lamp1 mAb Cancer</p>		<p><b>cemiplimab<sup>(4)</sup></b> <span>N</span></p> <p>PD-1 inhibitor Advanced BCC</p>	<p><b>Tuberculosis</b></p> <p>Recombinant subunit vaccine</p>	<p><b>sotagliflozin</b> <span>N</span></p> <p>Oral SGLT-1&amp;2 inhibitor Type 1 &amp; Type 2 Diabetes</p>	<p><span>R</span> Registration Study (other than Phase 3)</p>
<p><b>SAR439459</b> <span>N</span></p> <p>TGFβ inhibition mAb Metastatic Melanoma</p>		<p><b>isatuximab</b> <span>N</span></p> <p>Anti-CD38 naked mAb Acute Lymphoblastic Leukemia</p>	<p><b>Adacel+</b></p> <p>Tdap booster</p>	<p><b>SAR341402</b> <span>N</span></p> <p>Rapid acting insulin Type 1 &amp; Type 2 Diabetes</p>	<p>Immuno-inflammation</p>
<p><b>cemiplimab<sup>(4)</sup></b> <span>N</span></p> <p>PD-1 inhibitor Head &amp; Neck Cancer</p>		<p><b>SAR566658</b> <span>N</span></p> <p>Maytansin-loaded anti-CA6 mAb Solid Tumors</p>	<p><b>Shan 6</b></p> <p>DTP-HepB-Polio-Hib Pediatric hexavalent vaccine</p>	<p><b>Clostridium difficile</b></p> <p>Toxoid vaccine</p>	<p>MS, Neuro, Ophthalmology</p>
		<p><span>R</span> <b>olipudase alfa</b> <span>N</span></p> <p>mASM Deficiency Acid Sphingomyelinase Deficiency<sup>(2)</sup></p>	<p><b>HIV</b></p> <p>Viral vector prime &amp; rgp120 boost vaccine</p>	<p><b>Fluzone® QIV HD</b></p> <p>Quadrivalent inactivated influenza vaccine - High dose</p>	<p>Oncology</p>
		<p><b>vanglustat</b> <span>N</span></p> <p>Oral GCS inhibitor Gaucher related Parkinson's Disease, Gaucher Disease Type 3, Fabry Disease</p>	<p><b>RSV mAbs<sup>(3)</sup></b></p> <p>Respiratory syncytial virus Monoclonal antibody</p>	<p><b>Pediatric pentavalent vaccine</b></p> <p>DTP-Polio-Hib Japan</p>	<p>Rare Disease</p>
				<p><b>Men Quad TT</b></p> <p>Advanced meningococcal ACYW conjugate vaccine</p>	<p>Diabetes Solutions</p>
					<p>Cardiovascular &amp; metabolism</p>
					<p>Infectious Diseases</p>
					<p>Vaccines</p>

(1) Also known as MYK491

(2) Also known as Niemann Pick type B

(3) Also known as SP0232 and MEDI8897

(4) Also known as SAR439684 and REGN2810

(5) Also known as SAR439152 and as MYK461

(6) On clinical hold